Coffee Morning November
by ALK+ International
£890.00
raised by 14 donations
of £100.00 Target Goal
890%
The Story
My name is Margaret and I have lived in Hextable village for over 40 years with my two sons, one of which was diagnosed with a very rare type of lung cancer when he was just 33 years old. Please join me to help raise money for more research into this rare type of cancer that can affect anyone regardless of age or smokerstatus.
Come and join us for Coffee and Cake - £5.00
There will also be a book stall and a woolly hat sale.
Coffee Morning Hextable Heritage Centre Saturday 25th November from 10.30am - 12.30pm
Hextable Heritage Centre, 8 Crawfords, Hextable, BR8 7PL.
ALK+ cancer is a type of genetic mutation cancer with no known cause, and no known cure ALK+ cancers are found in patients of all ages, although on average these patients tend to be younger and it is predominantly found in the lungs.
ALK+ International is a patient and family-led charity, created with a single mission: to improve the life expectancy for ALK+ cancer patients. Visit our website to find out more: alkinternational.org
ALK+ International
ALK+ International is a patient and family-led charity, created with a single mission: to improve the life expectancy for ALK+ cancer patients.
100% of all funds raised will go towards research.
ALK+ cancer is a type of genetic mutation cancer with no known cause, and no known cure once it has spread to other parts of the body. It is caused by a mutation or fusion of the ALK gene. ALK+ cancers are found in patients of all ages, although on average these patients tend to be younger.
ALK+ lung cancer occurs in approximately 5% of all non small cell lung cancer patients. However, it occurs in approximately 30% of lung cancer patients diagnosed under age 40. Around half of ALK+ lung cancer patients are diagnosed before the age of 50. It is estimated that there are approximately 100,000 ALK+ lung cancer patients diagnosed worldwide every year.
It is estimated that there are more than 10,000 ALK+ lung cancer patients living in the UK. The overall ALK+ figure is likely to be higher, given that ALK+ mutations drive other cancers.
Since the discovery of ALK+ cancer in 2007, there have been incredible advances in the range of life saving treatments. As with other cancers linked with genetic mutations, ALK+ cancer is treated with targeted therapies - a class of drugs that precisely target and inhibit cancer cell growth with considerably fewer side effects than traditional treatments. While this makes ALK+ cancer treatable, it is still incurable. ALK+ patients will develop resistance to their medication or experience further mutations, rendering their treatment ineffective. Research is needed into further treatments, to provide either more targeted therapies or diversify treatment options.
Learn more about us at www.alkinternational.org
"Donation from friend Lorraine and Joan Chick"
Margaret donated £20.00 on 2024/1/17 at 16:47.